Patients in RCT@ received intravenous placebo , @-mg tabalumab or @-mg tabalumab every @weeks , and patients in RCT@ received subcutaneous placebo or @ - , @ - , @ - , @ - , @ - or @-mg tabalumab every @weeks ( Q@W ) .